title: Down's syndrome is associated with increased 8,12-iso-iPF2alpha-VI levels: evidence for enhanced lipid peroxidation in vivo.
abstract: Postmortem and in vitro studies have shown that oxidative stress plays a role in the pathogenesis of many of the clinical features of Down's syndrome. The isoprostane 8,12-iso-iPF2alpha-VI is a specific marker of lipid peroxidation. We found elevated levels of this isoprostane in urine samples of subjects with Down's syndrome compared with those of matched controls, which correlated with the duration of the disease. These results suggest that increased in vivo lipid peroxidation is a prominent component early in the course of Down's syndrome.
authors.affiliation: The Center for Experimental Therapeutics, University of Pennsylvania, Philadelphia 19104, USA.
authors.forename: D
authors.initials: D
authors.lastname: Praticò
authors.forename: L
authors.initials: L
authors.lastname: Iuliano
authors.forename: G
authors.initials: G
authors.lastname: Amerio
authors.forename: L X
authors.initials: LX
authors.lastname: Tang
authors.forename: J
authors.initials: J
authors.lastname: Rokach
authors.forename: G
authors.initials: G
authors.lastname: Sabatino
authors.forename: F
authors.initials: F
authors.lastname: Violi
mesh_terms: D000293:Adolescent; D000704:Analysis of Variance; D002648:Child; D002675:Child, Preschool; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000652:urine*; D004314:Down Syndrome / Q000652:urine*; D005260:Female; D006801:Humans; D007223:Infant; D015227:Lipid Peroxidation; D008297:Male; D012680:Sensitivity and Specificity
chemical_list: C115626:8,12-iso-isoprostane F2alpha-VI; D015237:Dinoprost